Nasdaq
$19.71▼ 0.08%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $3.38BShares out 1.700M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 1d agoAfter-hours26.10.24 05:518-KKey event#●●●#●●●
ACADIA PHARMACEUTICALS INC
Dr. Elizabeth H.Z. Thompson, Executive Vice President and Head of Research and Development at Acadia Pharmaceuticals, departed from the company effective October 23, 2026. She will provide limited consulting services until December 31, 2026, while the company is currently searching for her successor.…more
$19.71-0.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.24After-hours26.09.25 06:118-KKey event
ACADIA PHARMACEUTICALS INC
Acadia Pharmaceuticals announced topline results from the Phase 2 RADIANT study of remlifanserin for Alzheimer's disease psychosis, showing improvement in the key secondary endpoint CGI-S-ADP for the 60 mg dose. Although the primary endpoint SAPS-H+D narrowly missed statistical significance (p=0.0603), the company plans to continue Phase 3 development while removing the 30 mg dosage arm based on favorable safety data.…more
$19.71-0.08%vs prev closeView filingShare - 9.11After-hours26.09.12 06:158-KKey event
ACADIA PHARMACEUTICALS INC
Acadia Pharmaceuticals has reached a settlement regarding a stockholder derivative action involving allegations of misleading disclosures related to drug approval and insider trading. The company has agreed to implement corporate governance reforms for a minimum of four years and will pay $1.5 million in attorneys' fees to the plaintiffs' counsel.…more
$19.71-0.08%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.24Regular26.09.25 02:43Bullish#●●●#●●●
Acadia Pharmaceuticals Misses Primary Endpoint in Phase 2 Alzheimer’s Trial…more
Acadia Pharmaceuticals shares fell after its Alzheimer’s psychosis drug candidate failed to meet the primary endpoint for statistical significance in a Phase 2 trial. Despite the setback, the company intends to proceed with Phase 3 development using a 60 mg dosage.…more
$19.71-0.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.24Pre-market26.09.24 20:04
●●●●●●●● ●●●●● ●●●●●●
Acadia Pharmaceuticals will proceed to Phase 3 trials for its Alzheimer’s psychosis drug after achieving positive secondary endpoints despite narrowly missing the primary endpoint. The company reported a favorable safety profile and plans to refine its Phase 3 study design based on these findings.…more
$19.71-0.08%vs prev closeShareBenzinga - 9.11After-hours26.09.12 06:21
●●●●●●●● ●●●●● ●●●●●●
Acadia Pharmaceuticals has received preliminary court approval for the settlement of a stockholder derivative action. The details of the settlement and related notices are available on the company's investor relations website.…more
$19.71-0.08%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report